Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Celgene
Study ID
NCT02635061
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ACY-241 — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days

Study Details

Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.

Key Dates

Start date
Aug 25, 2016
Status verified
May 2024
Primary completion
Jan 22, 2024
Completion
Jan 22, 2024

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ACY-241 in combination with nivolumab

Primary Outcome Measure

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: one to two years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Local Institution - 350BostonMassachusetts02215-

Find similar trials in Boston, MA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Local Institution - 350· Boston, MA

Related Studies